This clinical trial, sponsored by Ruijin Hospital, aims to evaluate the combined efficacy and safety of CAR T-cell therapy and Glofitamab in patients with relapsed/refractory large B-cell lymphoma exhibiting high-risk prognostic factors. The market for CAR T-cell therapies is expanding, particularly in hematologic malignancies, with increasing competition from other CAR T-cell products and bispecific antibodies. Successful outcomes could position this combination therapy as a viable treatment option, potentially capturing market share in a segment characterized by high unmet medical need. Diligence should focus on the competitive landscape, particularly the performance of existing therapies and ongoing trials targeting similar patient populations.